Expected and actual case ascertainment and treatment rates for children infected with hepatitis c in florida and the united states: Epidemiologic evidence from statewide and nationwide surveys

Journal of Pediatrics

Volumn 161, Issue 5, 2012, Pages 915-921

  Delgado Borrego, Aymin ^a,b   Smith, Lesley ^a   Jonas, Maureen M ^b   Hall, Cyndena A ^c   Negre, Betania ^a   Jordan, Sergio H ^a   Ogrodowicz, Matthew ^b   Raza, Roshan ^b   Ludwig, David A ^a   Miller, Tracie ^a   Lipshultz, Steven E ^a   Gonzalez Peralta, Regino ^d   Chung, Raymond T ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Department of Health ^*  (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

HCV; Hepatitis C virus; Institute of Medicine; IOM; Medical Emergency Relief International; MERLIN; National Health and Nutrition Examination Survey; NHANES; Sustained virologic response; SVR

Indexed keywords

HEPATITIS B ANTIBODY;

ADOLESCENT; ADULT; AWARENESS; CHILD; CONTROLLED STUDY; ETHNICITY; FEMALE; GASTROENTEROLOGIST; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL PRACTICE; MEDICAL SPECIALIST; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH; QUESTIONNAIRE; REVIEW; SCHOOL CHILD; UNITED STATES;

EID: 84867867556     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2012.05.002     Document Type: Article

References (31)

1. Hepatitis C - global prevalence (update) Wkly Epidemiol Rec 75 2000 18 19
2. A.E. Mitchell, H.M. Colvin, and R. Palmer Beasley Institute of Medicine recommendations for the prevention and control of hepatitis B and C Hepatology 51 2010 729 733
3. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl 1 2009 74 81
4. R. Jhaveri, W. Grant, T.L. Kauf, and J. McHutchison The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period J Pediatr 148 2006 353 358
5. M.J. Alter, D. Kruszon-Moran, O.V. Nainan, G.M. McQuillan, F. Gao, and L.A. Moyer The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
6. M. Kage, T. Fujisawa, K. Shiraki, T. Tanaka, A. Kimura, and K. Shimamatsu Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan Hepatology 26 1997 771 775
7. C. Garcia-Monzon, P. Jara, M. Fernandez-Bermejo, L. Hierro, E. Frauca, and C. Camarena Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients Hepatology 28 1998 1696 1701
8. K. Badizadegan, M.M. Jonas, M.J. Ott, S.P. Nelson, and A.R. Perez-Atayde Histopathology of the liver in children with chronic hepatitis C viral infection Hepatology 28 1998 1416 1423
9. M.A. El-Hawary, M.S. El-Raziky, G. Esmat, H. Soliman, A. Abouzied, and M. El-Raziky Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt World J Gastroenterol 13 2007 2846 2851
10. Z.D. Goodman, H.R. Makhlouf, L. Liu, W. Balistreri, R.P. Gonzalez-Peralta, and B. Haber Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial Hepatology 47 2008 836 843
11. F. Bortolotti, G. Verucchi, C. Camma, G. Cabibbo, L. Zancan, and G. Indolfi Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease Gastroenterology 134 2008 1900 1907
12. D.K. Strickland, J.J. Jenkins, and M.M. Hudson Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer J Pediatr Hematol Oncol 23 2001 527 529
13. R.P. Gonzalez-Peralta, M.R. Langham Jr., J.M. Andres, P. Mohan, P.M. Colombani, and M.K. Alford Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C J Pediatr Gastroenterol Nutr 48 2009 630 635
14. K.B. Schwarz, R.P. Gonzalez-Peralta, K.F. Murray, J.P. Molleston, B.A. Haber, and M.M. Jonas The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C Gastroenterology 140 2011 450 458 e1
15. S. Wirth, C. Ribes-Koninckx, M.A. Calzado, F. Bortolotti, L. Zancan, and P. Jara High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin J Hepatol 52 2010 501 507
16. L.S. Smith, M. Nelson, S. Naik, and J. Woten Telaprevir: An NS3/4A protease inhibitor for the treatment of chronic hepatitis C Ann Pharmacother 45 2011 639 648
17. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
18. K.E. Sherman, S.L. Flamm, and N. Afdhal Telaprevir in combination with peg-interferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: Final results of phase 3 ILLUMINATE study Hepatology 52 Suppl:400A-400A 2010
19. D. Swan, J. Long, O. Carr, J. Flanagan, H. Irish, and S. Keating Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration AIDS Patient Care STDS 24 2010 753 762
20. J. Grebely, K.A. Genoway, J.D. Raffa, G. Dhadwal, T. Rajan, and G. Showler Barriers associated with the treatment of hepatitis C virus infection among illicit drug users Drug Alcohol Depend 93 2008 141 147
21. K.K. Yan, G.L. Wong, V.W. Wong, and H.L. Chan Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital Dig Dis Sci 55 2010 3541 3547
22. J.D. Scott, A. Wald, M. Kitahata, E. Krantz, L. Drolette, and L. Corey Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population AIDS Patient Care STDS 23 2009 925 929
23. G.L. Armstrong, A. Wasley, E.P. Simard, G.M. McQuillan, W.L. Kuhnert, and M.J. Alter The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714
24. E. Minola, D. Prati, F. Suter, F. Maggiolo, F. Caprioli, and A. Sonzogni Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C Blood 99 2002 4588 4591
25. M.A. Casiraghi, M. De Paschale, L. Romano, R. Biffi, A. Assi, and G. Binelli Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini-transfusions of blood given at birth Hepatology 39 2004 90 96
26. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521 e1-6
27. M.L. Volk Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 65 2010 1327 1329
28. B.L. Shneider, R. Gonzalez-Peralta, and E.A. Roberts Controversies in the management of pediatric liver disease: hepatitis B, C, and NAFLD: summary of a single topic conference Hepatology 44 2006 1344 1354
29. D. Sene, N. Limal, and P. Cacoub Hepatitis C virus-associated extrahepatic manifestations: a review Metab Brain Dis 19 2004 357 381
30. A. Craxi, G. Laffi, and A.L. Zignego Hepatitis C virus (HCV) infection: a systemic disease Mol Aspects Med 29 2008 85 95
31. K.P. Puchner, and T. Berg Extrahepatic manifestations of chronic hepatitis C virus infection Z Gastroenterol 47 2009 446 456